PROLIA Drug Profile

Summary for Tradename: PROLIA

High Confidence Patents:	49
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for PROLIA
Recent Clinical Trials:	See clinical trials for PROLIA

See drug prices for PROLIA

Recent Clinical Trials for PROLIA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Taiwan University Hospital	PHASE4
National Taiwan University Hospital, Yun-Lin Branch	PHASE4
Xentria, Inc.	PHASE3

See all PROLIA clinical trials

Pharmacology for PROLIA

Mechanism of Action	RANK Ligand Blocking Activity
Established Pharmacologic Class	RANK Ligand Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PROLIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PROLIA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,167,492	2035-12-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,421,987	2038-07-18	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,513,723	2034-12-09	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,583,397	2035-05-13	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,655,156	2039-01-29	DrugPatentWatch analysis and company disclosures
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,822,630	2040-02-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PROLIA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,006,091	2033-06-06	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,016,338	2036-12-20	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,047,398	2031-10-05	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,058,630	2037-05-22	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,065,934	2035-07-16	Patent claims search
Amgen Inc.	PROLIA	denosumab	Injection	125320	10,092,542	2037-06-21	Patent claims search

International Patents for PROLIA

Country	Patent Number	Estimated Expiration
Denmark	2270052
Australia	2018226416
Norway	345566
Philippines	12019502444
Denmark	2173861
World Intellectual Property Organization (WIPO)	2016089919

Supplementary Protection Certificates for PROLIA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
45/2010	Austria		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 MITTEILUNG 20100528
CA 2010 00031	Denmark
SPC/GB10/043	United Kingdom		PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR))(HUMAN MONOCLONAL AMG 162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG 162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526
SPC/GB10/044	United Kingdom		PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100528; UK EU/1/10/618/002 20100528; UK EU/1/10/618/003 20100528; UK EU/1/10/618/004 20100528
PA2010013	Lithuania		PRODUCT NAME: DENOSUMABUM; REGISTRATION NO/DATE: EU/1/10/618/001, 2010 05 26, EU/1/10/618/002, 2010 05 26, EU/1/10/618/003, 2010 05 26, EU/1/10/618/004 20100526
C300467	Netherlands		PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526

Market Dynamics and Financial Trajectory for Prolia

Last updated: February 19, 2026

What is Prolia?

Prolia (denosumab) is a monoclonal antibody developed by Amgen that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand). Approved by the FDA in 2010 for osteoporosis treatment in postmenopausal women and men at increased fracture risk, it is administered via subcutaneous injection every six months.

Market Size and Growth Drivers

Global Osteoporosis Market

The osteoporosis drug market reached approximately $13.5 billion in 2022, with Prolia capturing a significant share due to its clinical positioning and dosing regimen. The market is projected to grow at a compound annual growth rate (CAGR) of 4.7% through 2030, driven by aging populations and increasing osteoporosis awareness.

Prolia's Market Penetration

• 2010-2022: Rapid adoption across North America and Europe.
• 2022: Estimated sales of $4.1 billion globally.
• Market penetration: 15% of osteoporosis patients receive biologics; Prolia is the leading brand within this segment.

Key Growth Factors

• Aging demographics in developed markets.
• Better clinical outcomes compared to bisphosphonates.
• Extension approvals for additional indications, such as glucocorticoid-induced osteoporosis and prostate cancer-related bone loss.

Competitive Landscape

Primary competitors include:

• Xgeva (denosumab): Same molecule, primarily for bone metastases.
• Bisphosphonates: Alendronate, zoledronic acid.
• Other biologics: Romosozumab (Evenity), which faces approval and commercial threats.

Market share for Prolia has been relatively stable at approximately 70% within biologic osteoporosis treatments, with new entrants and generics influencing future dynamics.

Regulatory Trends and Approvals

Expanded Indications

• 2017: Approval for glucocorticoid-induced osteoporosis.
• 2021: FDA approves Prolia for men at high fracture risk, expanding the potential patient pool.

Patent and Patent Challenges

• Original patent expiration scheduled for 2025 in the US, with patent cliff threats increasing competition.
• Amgen pursued various patent extensions and legal defenses to prolong exclusivity.

Biosimilar Landscape

• Multiple biosimilar candidates in late-stage development.
• Anticipated entry could decrease Prolia's US and European sales by an estimated 20-30%, starting from 2025 onward.

Financial Trajectory

Revenue Projections

Year	Estimated Revenue (USD Billion)	Assumptions
2022	4.1	Mature market penetration
2023	4.3	Slight growth driven by expanded approvals
2025	4.5	Pre-biosimilar market, patent expiry concerns begin
2026	3.1	Projected 25-30% decline due to biosimilar competition
2030	2.5	Continued erosion absent new indications or formulations

Cost and Pricing Trends

• Average selling price (ASP) in the US: approximately $2,600 per injection.
• Price pressures from biosimilars and payers could reduce ASP by 10-15% by mid-decade.
• Reimbursement policies favor biosimilars, further impacting revenue.

R&D and Pipeline Potential

Amgen invests heavily in pipeline expansion, with potential complementary drugs such as:

• Romosozumab: Dual anabolic and antiresorptive activity.
• Next-generation RANKL inhibitors: Under development for enhanced efficacy.

Key Market Risks and Opportunities

Risks

• Patent expiration in major markets.
• Biosimilar entry eroding market share.
• Competition from oral or alternative therapies improving adherence.

Opportunities

• New indications for osteoporosis and other bone diseases.
• Geographic expansion into emerging markets.
• Development of long-acting formulations to improve compliance.

Summary

Prolia maintains a leading position in the biologic osteoporosis treatment segment with consistent revenue streams driven by favorable clinical data and dosing simplicity. Patent protections and regulatory approvals support steady growth until patent cliffs impact market share. The imminent biosimilar entry poses the most significant risk to its financial trajectory.

Key Takeaways

• Prolia generated $4.1 billion in 2022 global sales with steady growth.
• Market expansion is driven by aging populations and expanding indications.
• Patent expiration in 2025 will lead to biosimilar competition, risking 20-30% revenue decline.
• Pricing pressures and biosimilar penetration could erode revenue further by 2030.
• Diversification into new indications and formulations remains critical for sustained growth.

FAQs

1. When is Prolia's patent expected to expire?
Patent in the US expires in 2025; patent protections in other regions vary.

2. How might biosimilars impact Prolia’s sales?
Biosimilars could reduce sales by 20-30% starting around 2025 due to price competition.

3. What additional indications could extend Prolia’s market viability?
Potential new uses include prevention of osteoporosis in men and treatment of other bone-related conditions.

4. How does Prolia compare to oral bisphosphonates?
Prolia offers better compliance with twice-yearly dosing but at higher cost and with injection site risks.

5. What is the outlook for Prolia in emerging markets?
Market penetration remains limited; expansion depends on pricing, reimbursement, and local healthcare policies.

---

References

[1] MarketResearch.com. (2023). Global osteoporosis drugs market size & forecast.
[2] Amgen Inc. (2022). Annual report.
[3] FDA. (2010). Prolia (denosumab) prescribing information.
[4] EvaluatePharma. (2023). Osteoporosis drug sales forecast.
[5] IMS Health. (2022). Biologic market share analysis.